Compare SHEN & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHEN | PRTA |
|---|---|---|
| Founded | 1902 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 634.6M | 538.3M |
| IPO Year | N/A | N/A |
| Metric | SHEN | PRTA |
|---|---|---|
| Price | $11.83 | $8.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $26.00 | $18.86 |
| AVG Volume (30 Days) | 274.0K | ★ 496.8K |
| Earning Date | 02-19-2026 | 02-19-2026 |
| Dividend Yield | ★ 0.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $351,674,000.00 | $11,786,000.00 |
| Revenue This Year | $10.77 | N/A |
| Revenue Next Year | $4.96 | $1,183.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.24 | N/A |
| 52 Week Low | $9.67 | $4.32 |
| 52 Week High | $15.84 | $16.67 |
| Indicator | SHEN | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 56.11 | 39.86 |
| Support Level | $11.69 | $8.39 |
| Resistance Level | $12.24 | $9.05 |
| Average True Range (ATR) | 0.38 | 0.50 |
| MACD | 0.05 | -0.07 |
| Stochastic Oscillator | 68.75 | 17.76 |
Shenandoah Telecommunications Company, with its subsidiaries, provides various broadband communication products and services via its wireless, cable, fiber optic, and fixed wireless networks to customers in the Mid-Atlantic United States. The company operates through one business unit: Broadband. The broadband segment provides broadband Internet, video, and voice services to residential and commercial customers. The broadband segment generates the vast majority of the company's revenue, with the bulk of sales flowing from residential and small, and medium businesses within the broadband unit.
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.